{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ADME"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADME","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADME\",,,,,undefined,":{"symbol":"ADME","market":"US","secType":"STK","nameCN":"Aptus Drawdown Managed Equity ETF","latestPrice":46.6482,"timestamp":1750449600000,"preClose":46.7338,"halted":0,"volume":12648,"hourTrading":{"tag":"盘后","latestPrice":46.68,"preClose":46.6482,"latestTime":"16:04 EDT","volume":2,"amount":93.2964,"timestamp":1750449853723},"delay":0,"floatShares":4591755,"shares":4591755,"eps":0,"marketStatus":"Not Yet Opened","change":-0.0856,"latestTime":"06-20 16:00:00 EDT","open":46.785,"high":46.8719,"low":46.5801,"amount":589920.9485,"amplitude":0.006244,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":0,"adr":0,"exchange":"AMEX","adjPreClose":46.7338,"sharesOutstanding":4591755,"nav":46.74,"aum":214618628.7,"dividendRate":0.004502,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":46.68,"preClose":46.6482,"latestTime":"16:04 EDT","volume":2,"amount":93.2964,"timestamp":1750449853723},"volumeRatio":0.9419685400649895},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADME\",,,,,undefined,":{"symbol":"ADME","floatShares":4591755,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.9419685400649895,"shares":4591755,"dividePrice":0.21,"high":46.8719,"amplitude":0.006244,"preClose":46.7338,"low":46.5801,"week52Low":39.85,"pbRate":"--","week52High":48.565,"institutionHeld":0,"latestPrice":46.6482,"eps":0,"divideRate":0.004502,"volume":12648,"delay":0,"ttmEps":0,"open":46.785,"prevYearClose":46.7141,"prevWeekClose":46.8466,"prevMonthClose":46.4089,"prevQuarterClose":44.405,"fiveDayClose":47.1851,"twentyDayClose":45.9382,"sixtyDayClose":45.595},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ADME\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADME\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521403218","title":"The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2521403218","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521403218?lang=en_us&edition=fundamental","pubTime":"2025-03-21 16:46","pubTimestamp":1742546760,"startTime":"0","endTime":"0","summary":"Chicago, IL – March 21, 2025 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sarepta Therapeutics SRPT, Incyte INCY, Gilead Sciences, Inc. GILD and VTv Therapeutics Inc. VTVT.It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Sarepta Therapeutics crashed following a report of a patient's death after treatment with Elevidys. Incyte also declined after study data disappointed investors.GILD boasts a market-leading portfolio of HIV treatments both for treating the disease and prevention. The company has two drugs for HIV prevention in its portfolio – Descovy and Truvada. Gilead to looking to get another drug approved for HIV prevention – lenacapavir.Per the report, while programs do provide free pre-exposure prophylaxis, reductions to the s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-sarepta-084600176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BSNM7G36.USD","LU0889565916.HKD","IE0002270589.USD","BK4578","INCY","LU1585245621.USD","LU0234570918.USD","BK4166","LU0109394709.USD","BK4568","LU2089984988.USD","BK4588","LU0320765992.SGD","ADME","LU1066051498.USD","SRPT","IE00BZ1G4Q59.USD","BK4583","IE00BFTCPJ56.SGD","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","IE00B19Z3581.USD","IE0009355771.USD","LU1571399168.USD","LU1839511570.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","QD","BK4566","IE00B3T34201.USD","LU2468319806.SGD","BK4585","BK4563","BK4139","IE0002141913.USD","LU0058720904.USD","LU2087621335.USD","VTVT","BK4503","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD","GILD","BK4550","IE00BJT1NW94.SGD","BK4532","LU1430594728.SGD"],"gpt_icon":0},{"id":"2521493395","title":"Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2521493395","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521493395?lang=en_us&edition=fundamental","pubTime":"2025-03-21 00:45","pubTimestamp":1742489100,"startTime":"0","endTime":"0","summary":"It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Sarepta Therapeutics SRPT crashed following report of a patient death after treatment with Elevidys. Incyte INCY also declined after study data disappointed investors.Shares of Sarepta Therapeutics plunged earlier in the week after it reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy .Per the company, this patient died of acute liver failure. While acute liver injury is a known risk of Elevidys, this is the first time a death has been reported of anyone taking the therapy. However, Sarepta stated that the patient also had a recent cytomegalovirus  infection, which may have contributed to the outcome, as CMV can damage the liver.HS, a chronic inflammatory skin condition, is characterized by painful nodules and abscesses.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-patient-death-164500168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2468319806.SGD","LU1066051498.USD","IE00B19Z3B42.SGD","BK4578","LU1571399168.USD","LU1839511570.USD","BK4503","IE00BJJMRZ35.SGD","IE00BZ1G4Q59.USD","BK4568","IE00BJT1NW94.SGD","GILD","LU2087621335.USD","INCY","BK4532","IE0009355771.USD","LU1585245621.USD","SRPT","ADME","IE00B19Z3581.USD","VTVT","LU0889565916.HKD","IE00BKVL7J92.USD","IE0002141913.USD","IE00B7SZLL34.SGD","IE00BFTCPJ56.SGD","LU1430594728.SGD","LU0320765992.SGD","IE00B2B36J28.USD","LU1066053197.SGD","LU0058720904.USD","LU2089984988.USD","BK4583","LU0234570918.USD","BK4585","BK4563","BK4139","BK4550","BK4166","BK4566","IE0002270589.USD","LU0109394709.USD","QD","IE00B3T34201.USD","LU0289739699.SGD","BK4588","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2510385004","title":"Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia","url":"https://stock-news.laohu8.com/highlight/detail?id=2510385004","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510385004?lang=en_us&edition=fundamental","pubTime":"2025-02-11 20:45","pubTimestamp":1739277900,"startTime":"0","endTime":"0","summary":"No serious side effects or discomfort observed  Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb.  11, 2025  (GLOBE NEWSWIRE) --  Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3024071/0/en/Silo-Pharma-Announces-Positive-Initial-Pharmacokinetic-Safety-and-Tolerability-Study-of-SP-26-for-Chronic-Pain-and-Fibromyalgia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADME","BK4135","CNS"],"gpt_icon":0},{"id":"2501203113","title":"Final Study Completed for Cingulate’s Lead Asset CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2501203113","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501203113?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:30","pubTimestamp":1736253000,"startTime":"0","endTime":"0","summary":"No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025. KANSAS CITY, Kan., Jan. 07, 2025  -- Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release  drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has completed its final FDA-required study, which is a food effect study, for CTx-1301  for the treatment of Attention Deficit Hyperactivity Disorder .The primary PK endpoints were maximum concentration  during the first 28 hours after dosing, and the total amount of the active pharmaceutical ingredient , dexmethylphenidate, in the blood  from dosing to the time of the last measured concentration  and from dosing taken to the limit as the end time becomes arbitrarily large . Overall, the effect of food on the PK of orally administered long-acting stimulants is generally minimal: following a high-fat meal, there is potential for the ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/final-study-completed-cingulate-lead-123000121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","ABVC","ADHD","BK4218","BK4551","CING","BK4503","BK4139","BK4535","API","PK","CINGW","BK4023","BK4007","ADME"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADME\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"ADME","amount":0.056234,"announcedDate":"2025-03-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"Aptus Drawdown Managed Equity ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":"2025-03-31"},{"date":"2024-12-30","symbol":"ADME","amount":0.04270086,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-30","defaultRemindTime":1735569000000,"name":"Aptus Drawdown Managed Equity ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-30","currency":"USD","dateTimestamp":1735534800000,"payDate":"2024-12-31"},{"date":"2024-09-27","symbol":"ADME","amount":0.052813,"announcedDate":"2024-09-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-27","defaultRemindTime":1727443800000,"name":"Aptus Drawdown Managed Equity ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-27","currency":"USD","dateTimestamp":1727409600000,"payDate":"2024-09-30"},{"date":"2024-06-27","symbol":"ADME","amount":0.05503,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-27","defaultRemindTime":1719495000000,"name":"Aptus Drawdown Managed Equity ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-27","currency":"USD","dateTimestamp":1719460800000,"payDate":"2024-06-28"},{"date":"2024-03-26","symbol":"ADME","amount":0.068534,"announcedDate":"2024-03-25","type":"dividend","market":"US","newRecordDate":"2024-03-27","defaultRemindTime":1711459800000,"name":"Aptus Drawdown Managed Equity ETF","recordDate":"2024-03-28","payableDate":"2024-03-27","currency":"USD","dateTimestamp":1711425600000,"payDate":"2024-03-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADME\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-03","value":0.178221,"currency":"USD"},{"executeDate":"2018-12-28","recordDate":"2018-12-31","paymentDate":"2019-01-02","value":0.242457,"currency":"USD"},{"executeDate":"2019-12-24","recordDate":"2019-12-26","paymentDate":"2019-12-27","value":0.21310878,"currency":"USD"},{"executeDate":"2020-03-17","recordDate":"2020-03-18","paymentDate":"2020-03-19","value":0.0487927,"currency":"USD"},{"executeDate":"2020-06-16","recordDate":"2020-06-17","paymentDate":"2020-06-18","value":0.0366754,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADME\",market:\"US\",delay:false,,,undefined,":{}}}